ACADL and esophageal squamous cell carcinoma: Despite using different scoring systems, immunohistochemistry (IHC) studies have found a high expression of LCAD in 45–50% of patients with hepatocellular carcinoma (HCC) [20,21] and in 48.9% of patients with esophageal squamous cell carcinoma [22].